Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusion are effective treatment modalities for various hematological malignancies. Their therapeutic effect, the graft-versus-tumor (GvT) effect, is based mainly on an alloimmune response of donor T cells directed at tumor cells, in which differences in the expression of minor histocompatibility Ags (mHags) on the cells of the patient and donor have a crucial role. However, these differences are also responsible for induction of sometimes detrimental GvHD. As relapse and development of GvHD pose major threats for a large proportion of allotransplanted patients, additional therapeutic strategies are required. To augment the GvT response without increasing the risk of GvHD, specific mHagdirected immunotherapeutic strategies have been developed. Over the past years, much effort has been put into the identification of therapeutically relevant mHags to enable these strategies for a substantial proportion of patients. Currently, the concept of mHag-directed immunotherapy is tested in clinical trials on feasibility, safety and efficacy. In this review, we will summarize the recent developments in mHag identification and the clinical data on mHag-specific immune responses and mHag-directed therapies in patients with hematological malignancies. Finally, we will outline the current challenges and future prospectives in the field.
THE ROLE OF MINOR HISTOCOMPATIBILITY AGS IN GVT AND GVHD
Allogeneic stem cell transplantation (allo-SCT), either alone or followed by donor lymphocyte infusion (DLI), is a potentially curative treatment for various hematological malignancies. Essential for the antitumor effect is an immune response of donor T cells, and, to a lesser extent, of NK and B cells, already present in the graft, against persistent tumor cells. In the allogeneic transplantation setting, donor T cells attacking the tumor cells are frequently directed at host (allo-)specific Ags rather than tumor-specific Ags. 1 Therefore, the therapeutic graft-versus-tumor effect (GvT) is often accompanied by sometimes deleterious GvHD. In an HLA-matched transplant setting, the T-cell alloreactivity leading to both GvT and GvHD is caused by the recognition of minor histocompatibility Ags (mHags) presented by the cells of the recipient to donor T cells. These mHags are polymorphic HLA-bound peptides that differ between donor and recipient as they are degradation products of cellular proteins encoded by polymorphic genes. These polymorphisms between the host and the donor occur at the level of single or multiple base pairs, due to either single-nucleotide polymorphisms (SNPs), base pair insertions or deletions (indels) or copy number variations (CNVs). In contrast to several tumor-associated Ags, no self-recognition for mHags occurs and therefore no tolerance is induced, leading to potent donor T-cell responses ( Figure 1a) .
Depending on the tissue distribution of the polymorphic genes, mHags are either broadly expressed or are expressed in a hematopoietic-specific manner. According to current thinking, broadly expressed mHags can give rise to both GvHD and GvT, whereas the mHags exclusively expressed on hematopoietic cells can give rise to a specific GvT effect ( Figure 1b) . 2, 3 Based on this principle, mHags with a strict hematopoietic tissue restriction are considered ideal targets for immunotherapy in patients with residual or relapsing disease after allo-SCT, because they create the opportunity to separate GvT from GvHD. 4, 5 CLINICAL APPLICABILITY OF mHAGS As the polymorphic mHags are always presented by a certain HLA allele, there are several restrictions for the application of mHagspecific therapy: first, a genetic mHag mismatch between recipient and donor is required; second, the mismatched mHag gene needs to be expressed only on hematopoietic cells and finally donor and recipient need to express the appropriate HLA molecule for presentation of the specific mHag epitope. Thus, only a small group of patients can be treated with each mHag, and because of this individual applicability, the characterization of many mHags is necessary to enable broad implementation of mHag-based immunotherapy. Therefore, since 1998, the identification of hematopoietic-specific mHags has become a major goal of several investigators, devoted to enabling this difficult but ideal therapy for a large group of patients. Tables 1 and 2 represents a summary of all identified mHags with their molecular characteristics and additional clinical information on the selection of hematopoieticspecific mHags, respectively. Now, after the identification of around 50 mHags, over 35% of allotransplanted patients are potential candidates for this targeted therapy. This empirical percentage matches our previous calculations (with calculated applicability per mHag = HLA frequency × (mHag frequency × allelic variant frequency). 6 The current percentage is just large enough to test the feasibility and effectiveness of mHag-based immunotherapy strategies in selected patient groups.
Apart from their immunotherapeutic potential, a recent study indicated another potential clinical value of mHags: in a gendermismatched setting (female-to-male allo-SCT), the development of Ab responses against male-specific HY-mHags as early as 3 months after transplantation predicted chronic GvHD and the risk of nonrelapse mortality. 7, 8 Thus, Abs against mHags may represent early biomarkers of GvHD and could therefore possibly be of value in therapeutic decision making in GvHD. This encourages research toward identification of new mHags that are able to induce Ab responses after allo-SCT.
PROGRESS IN mHAG IDENTIFICATION METHODS
The molecular characterization of epitopes recognized by mHagspecific T-cell clones isolated from an allo-SCT recipient has been the traditional and the most successful strategy for identification of mHags. As the genetic origin of mHags was initially unknown, laborious and technically demanding methods were used for this purpose, such as peptide elution from HLA molecules or screening of cDNA libraries derived from mHag-positive target cells. [9] [10] [11] [12] [13] When it was understood that the polymorphic mHag peptides were, in fact, encoded by naturally inherited genetic variations, more efficient genetic identification techniques were introduced. In general, all these techniques aim at the identification of the genetic polymorphism encoding for the mHags via correlation analyses, in which a significant association is sought between the mHag phenotypes of a large number of individuals and known genetic markers in the genome of these individuals. For this purpose, many investigators made use of large pedigrees from the CEPH reference family collections, 14 and also self-assembled panels of individuals were used. 15 The mHag phenotypes of these individuals were usually determined by measuring the response of mHag-specific T-cell clones to Epstein-Barr virus-transformed B cells derived from those individuals. In the very first approach, the genomic locus of the mHag was identified by pairwise correlation of the mHag phenotypes with about 32 000 SNPs and microsatellite markers throughout the whole genome. 16 Nonetheless, this strategy was abandoned after the identification of mHags LRH-1, ACC1 and ACC2, 17, 18 because for several other mHags the identified genetic locus was too large to precisely identify the mHag. 6, 19, 20 The association of mHag phenotypes with individual SNPs spread throughout the genome appeared a more feasible strategy. The genetic polymorphism information required for these analyses was frequently derived from the HapMap project including 44 × 10 6 SNP genotypes for different ethnical populations. 21 Making use of the fact that several of the CEPH family members were included as trios (father-mother-child) in the databases of the HapMap Project, we developed a powerful and convenient genome-wide association study (GWAS). Based on the Mendelian inheritance pattern of mHags, we could determine the mHag zygosities for many individuals from their mHag phenotypes. Using this extra information in the GWAS analyses, we could rapidly identify the mHags CD19 L , SLC19A1 R and UTA2-1 L . 6, [21] [22] [23] IMPLEMENTING THE 1000 GENOMES PROJECT IN mHAG IDENTIFICATION STRATEGIES Although efficient and often successful, the above-described genetic correlation strategies were still unable to identify the target Ag of a number of mHag-specific T-cell clones, probably because of the limited number of genetic variations represented in the genetic databases. Therefore, we recently further improved the genetic correlation analyses by the implementation of the 1000 Genomes Project. This very detailed set of genetic variants, genotypes and haplotypes currently includes 79 × 10 6 variations of 2535 individuals from 26 ethnic populations. In addition to SNPs, the 1000 Genomes Project also contains CNVs, indels and complex short substitutions, thus covering 499% of all genetic variations with as low as 5% frequency. Indeed, using this new strategy it was possible to reidentify all previously discovered mHags and we have also identified new, mHag UTDP4-2, which could not be identified using all other previously developed techniques. 24 Recipient cell 
IDENTIFICATION OF mHAGS BY REVERSE IMMUNOLOGY STRATEGY
As the therapeutically relevant mHags are derived from hematopoietic-specific proteins, we and others have also put effort in the identification of mHags using the so-called 'reverse immunology' strategy, which is basically based on predicting T-cell epitopes on known proteins using computer algorithms. This strategy has been highly successful for the identification of several tumor-associated Ags and also contributed to the discovery of mHags. 25, 26 Over the past decades, T-cell epitope prediction algorithms based on factors such as HLA binding, proteasomal cleavage and TAP (transporter-associated processing) transport were improved and used to predict polymorphic T-cell epitopes present on hematopoietic-restricted proteins with a favorable mHag phenotype frequency. 5, 27 These strategies, however, had limited success, mainly because of the prediction of significant numbers of false-positive and false-negative candidates. 5 To overcome such drawbacks, in recent research the mHag selection algorithms were applied to identify candidate peptides within a large pool of peptides eluted from HLA molecules. Screening the donor blood for the presence of T cells specific for these candidates with MHC multimers led to the 
Abbreviations: GLA = genetic linkage analysis; GWAS = genome-wide association screening; IR = immune response; 1000GP = 1000 Genomes Project.
identification of two mHags, thereby demonstrating the 'proof of principle' of this new strategy. 28 Nonetheless, the technique seems to require significant improvement as the number of identified mHags from the whole HLA ligandome is low, and it failed to 'reidentify' already known mHags. 29, 30 Possibly, the implementation of new insights, similar to those acquired using the 1000 Genomes Project, may improve the success rates of reverse immunology methods. 5, 24 A new bioinformatic algorithm was recently presented, based on a whole-exome sequencing study performed on several allo-SCT donor-recipient pairs. This whole-exome sequencing demonstrated a large amount of genetic variation existing between donors and recipients independent of HLA matching, indicating a great alloreactivity potential. In silico predictions on the likelihood of HLA presentation of the derived potential Ags led to the generation of a library of several thousands of putative new mHags. 31, 32 OBSERVATIONAL CLINICAL DATA ON mHAG-SPECIFIC RESPONSES Several studies in animal models have previously shown that tumors can be effectively eliminated by the infusion of mHagspecific T cells. 33, 34 Furthermore, the outgrowth of mHag-specific T cells after allo-SCT for hematological malignancies frequently coincides with clinical tumor responses. 35 However, clinical data showing an association between individual mHag mismatch and survival benefit due to GvT are limited, probably because this question has not been frequently addressed in large and appropriate cohorts. Many of the available studies did not investigate the relation between mHag mismatches and clinical antitumor effects. [36] [37] [38] [39] [40] One small sized study that did look into tumor responses actually reported worse disease-free and overall survival rates for HA-8-mismatched patients in comparison with non-mismatched patients. 41 However, for HY mismatches a reduced risk of relapse was clearly suggested, 42, 43 whereas for hematopoietic-specific mHags such as HA-1 an association between GvT and mHag mismatch was also demonstrated in a relatively large cohort of 285 HLA-A2-positive CML patients, but exclusively when GvHD was also present. 44, 45 Several follow-up studies were unable to demonstrate the association of specific mHag mismatches with either GvHD or GvT, possibly due to the small cohort size, 46 -48 but a recent study investigating a large number of patients did demonstrate improved disease-free survival when at least one mHag mismatch was present, particularly in multiple myeloma patients. 49 Moreover, in a large retrospective study, allo-SCT from female donors to male recipients was found to have significantly lower relapse rates in comparison with all other gender combinations, indicating an important GvT effect mediated by HY responses. On the other hand, non-relapse mortality was higher in the female-to-male group because of an increased incidence of severe GvHD. 50 Altogether, these reports confirm the presence of mHag-specific T cells in mHag-mismatched patients after allo-SCT and suggest an association of these mismatches with the development GvT, with GvT predominantly occurring in the setting of a certain level of background GvHD.
ADOPTIVE IMMUNOTHERAPY STRATEGIES DIRECTED AT mHAGS
In the past years, various immunotherapeutic strategies have been proposed toward improving mHag-directed T-cell responses, mainly adoptive T-cell therapy with ex vivo generated mHagspecific T cells or mHag-loaded dendritic cell (DC) vaccination.
In a first clinical trial, patients with acute leukemia or myelodysplastic syndrome were treated with the infusion of ex vivo cultured mHag-specific T cells. In this study, both the presence of transferred CTLs and clinical responses were observed in five of seven patients, indicating that the administered mHagspecific T cells may induce specific antitumor responses. However, in all cases these responses were short-lived. Moreover, three patients experienced severe pulmonary toxicity because the targeted mHags turned out to be expressed on bronchial epithelium also. These results emphasized the essential importance of the thorough control of the tissue restriction of the selected mHags for immunotherapy. 51 In the first trial targeting genuinely hematopoietic-specific mHags, three HA-1-mismatched patients were treated with HA-1-specific T-cell lines generated ex vivo after a long culturing period of at least 4 weeks. No toxic effects were observed and one patient had stable disease for 3 months. The other patients demonstrated no clinical responses. Moreover, no HA-1-specific T cells could be demonstrated in the peripheral blood after the infusions. Apparently, the long ex vivo culture of T cells resulted in their rapid apoptosis after infusion. 52 Currently, more efficient strategies are being developed and applied. One of these strategies is the generation of mHag-specific T cells by means of transfer of mHag-specific TCR genes. In this strategy, the possible recombination of the endogenous TCRs with the introduced TCR requires attention, as this may result in the generation of undesired allo-or autoreactivity, even though the TCR is introduced in virus-specific T cells. 3 A different strategy to target mHag HA-1 was recently undertaken by the generation of Abbreviations: mHag = minor histocompatibility Ag; MUD = matched unrelated donor.
Minor histocompatibility Agsan HA-1-specific chimeric Ag receptor (CAR), which was engineered by coupling the Ag recognition domain of a monoclonal Ab specific for the HA-1/HLA-A*02 complex to the transmembrane and intracellular signaling domains of CD28 and CD3-ζ, respectively. This strategy proved feasible in vitro, but yet requires very high Ag density to induce cytotoxicity. 53 Other challenges in the field of adoptive immunotherapy with ex vivo generated T cells lie in providing long-term memory and sufficient migration of the mHag-specific T cells to the bone marrow or other tumor localizations. 54 New trials will focus on these points and we can inform us more about the value of these therapies. A recent highly promising attempt in this direction is the generation of mHag-specific CTLs after Akt inhibition. This strategy proved to have superior expansion potential and induced high numbers of CTLs with a stem cell-like phenotype in vitro, as well as in animal models. 55 
THE ROLE OF DCS IN CANCER THERAPY
The alternative approach for adoptive immunotherapy is to stimulate present mHag-specific T cells in vivo by means of DC vaccination. This strategy could pose an attractive option in terms of effectiveness and feasibility. DCs constitute an important population of immune cells as they serve as a crucial bridge between the innate and adaptive immunity with their powerful Ag-presenting capacities. [56] [57] [58] [59] The discovery that DCs could easily be cultured in vitro from monocytes significantly facilitated the understanding of their biology and their clinical use. 60, 61 This has led to a huge number of clinical trials in which ex vivo generated and mature DCs, unloaded or loaded with tumor-associated Ags or other peptides were used as vaccines to induce antitumor responses. 62, 63 To date, there is compelling evidence that clinical application of DCs, administered either IV, intradermally or intranodally is feasible and safe. Furthermore, in many trials the DC vaccines appeared to be capable of inducing T-cell responses against the relevant tumor Ags. 64 
DC VACCINATION IN mHAG-DIRECTED IMMUNOTHERAPY AFTER ALLO-SCT
Although DC vaccination is until now mainly applied in an autologous setting, 54, 65, 66 it becomes clear that this strategy may also be beneficial to boost GvT responses in the setting of allo-SCT. Effective GvT appears to be dependent not only on immune-competent donor T cells but also on the presence of host DCs that efficiently present mismatched host Ags to donor T cells. 67, 68 Consistent with this idea, a number of studies have demonstrated that the development of GvHD and particularly GvT after allo-SCT depends on a mixed chimeric status of the patients. [67] [68] [69] [70] [71] [72] [73] Autologous DC vaccinations, together with DLI, could therefore be highly relevant for a number of hematological malignancies, especially for multiple myeloma, where allo-SCT results in a rapid replacement of host DCs by donor DCs, which may seriously affect the clinical outcome. [74] [75] [76] [77] Prompted by this idea, we have treated seven DLI-nonresponder myeloma patients with autologous monocyte-derived DCs (moDCs) together with an equivalent dose of DLI. Although this autologous DC vaccination could theoretically induce GvHD as well as GvT, it proved feasible and safe. All patients developed anti-host T-cell responses and responses against the control KLH Ag, but we did not detect mHag-specific T-cell responses in three patients with known mHag mismatches. Furthermore, only one patient, with a very low tumor load at the start of treatment, experienced a sustained clinical response with a molecular CR persisting over 5 years (manuscript in preparation). In the current trial, we attempt to improve the clinical efficacy of this autologous vaccination strategy by loading the DCs with selected hematopoietic mHag peptides, to skew the donor immune response toward these mHags present on the malignant cells (Figure 2 ). As this autologous strategy cannot be applied for each patient, we also use donor-derived DCs loaded with hematopoietic mHags as a source of vaccine in clinical trials.
METHODS OF AG LOADING
In the DC vaccination trials, the mHag loading strategy may be important for the induction of relevant responses. So far, we loaded DCs with short peptides representing the exact mHag epitope as this convenient technique has been shown to induce objective T-cell responses in other clinical trials. 78 Moreover, with the introduction of synthetic modifications in the short mHag peptides, their immunogenicity can be further improved, leading to more potent mHag-specific responses in preclinical models. 79, 80 On the other hand, there is a growing conviction that vaccination with long peptides would give rise to superior T-cell responses as these would lead to prolonged Ag presentation in comparison with short peptides. Furthermore, the long peptides may induce not only CD8+ CTLs but also CD4+ T-cell responses, which are considered to provide essential signals for licensing of CD8+ CTLs. Based on a similar idea, DCs are electroporated with mRNA encoding full-length proteins, leading to effective Ag presentation via the natural route of translation and peptide processing. 81, 82 In fact, a recently initiated clinical trial in RUMC (Radboud University Medical Center), the Netherlands, is investigating the possibility of improving the clinical outcome of allo-SCT by vaccination of patients with donor DCs electroporated with mRNA of five different hematopoietic mHags. Comparing the results of these similar trials with different Ag loading strategies will be interesting as some of the advantages of long peptides or mRNA electroporation strategies are theoretically not applicable for mHags. For instance, so far for none of the MHC class I mHags, a CD4 T-cell epitope has been identified in the polymorphic region. Furthermore, experiments with elongated HA-1 sequences have revealed no beneficial DC presentation of this peptide. 83 
SELECTION OF DC SOURCE AND TYPE
Long before moDCs were discovered, it was known that human peripheral blood contained rare subsets of DCs derived from myeloid and lymphoid hematopoietic precursor cells. 59 While the lymphoid lineage-derived plasmacytoid DCs express CD303+ (BDCA-2), myeloid DCs are found in the peripheral blood as CD1c+ (BDCA-1)-or CD141+ (BDCA-3)-expressing subsets. As vaccinations with moDCs have rarely induced clinical responses, over the past years attempts to use these naturally occurring DC subsets in clinical trials were intensified. [84] [85] [86] [87] For the clinical use, both subsets can be isolated from peripheral blood using their respective markers. In addition, myeloid DCs can also be cultured in vitro from CD34+ cells. Both DC types appear to be able to induce relevant T-cell responses in preclinical studies, and a clinical trial of plasmacytoid DC vaccination in 15 melanoma patients showed the development of specific immune responses in combination with improved overall survival rates. 88 As myeloid DCs and plasmacytoid DCs appear to synergize to induce antitumor CTLs, a logical approach could be to combine the two subsets in one vaccine. 87, 89 Still, clinical data are limited and a side-by-side comparison of naturally occurring DCs to moDCs is not (yet) available.
To avoid the need for selection and ex vivo culture of specific DC subsets, in the past decade the possibilities to selectively target-relevant Ags to DCs in vivo have been explored. In preclinical studies, it has been shown that various DC receptors can successfully be targeted and both humoral and cellular responses are effectively induced. This approach could therefore also be interesting to use in mHag-based therapies. 90, 91 FUTURE OPPORTUNITIES: IMMUNE CHECKPOINT BLOCKADE AND COMBINATION THERAPIES In the first series of vaccination studies, clinical effects have been modest despite the generation of tumor-specific CTLs, strongly suggesting that the tumors could evade the induced antitumor immunity. Among many factors that may contribute to tumor evasion, upregulation of inhibitory 'checkpoint' molecules on tumor cells and the presence of immunosuppressive cells such as Tregs and MDSCs in the tumor microenvironment have gained the most attention. 87, 92, 93 Therefore, combination of DC vaccination or adoptive T-cell transfer with additional measures circumventing these barriers may be beneficial. For instance, blocking antibodies for inhibitory molecules such as PD-1 and CTLA-4 have already proven to be effective as monotherapy in solid tumors and may be effectively combined with cellular immunotherapies. Currently, the combination of these checkpoint-blocking antibodies with DC vaccination is under investigation in preclinical studies. 94, 95 However, the importance of inhibitory molecules has also been shown in the setting of allo-SCT. In a study of 13 patients with relapsed hematological malignancy after allo-SCT, the administration of the CTLA-4 Ab ipilimumab was generally well tolerated and led to objective antitumor responses, particularly in the lymphoid malignancies. Only one case of mild GvHD occurred (ASH 2015, abstract 3964). In addition, blockade of PD-1 signaling with antibodies in experimental settings led to increased proliferation and cytokine production of HA-1-specific T cells in response to HA-1-expressing tumor cells. Moreover, knockdown of the PD ligands on mHag-loaded DCs resulted in enhanced induction of mHag-specific T cells. [96] [97] [98] These results have already led to the initiation of two current trials in which mHag-loaded moDCs silenced for PD-L1/2 with short hairpin RNAs are being used. Also, the induction of cell-adhesion-mediated immune resistance, in parallel to the well-known phenomenon of cell-adhesionmediated drug resistance, may have an important role in tumor escape from immunotherapy. Combination therapy with specific targeting of adhesion molecules or apoptotic pathways involved in cell-adhesion-mediated immune resistance could therefore contribute to the success of mHag-specific therapies. 99 
CONCLUSION
In the treatment of hematological malignancies after allogeneic SCT, mHag-specific donor T cells are able to induce a beneficial GvT effect. As identification strategies continue to improve, an enlarging arsenal of mHags becomes available, enabling us to carry out mHag-directed immunotherapy trials. Various research groups are currently concerned with the optimization of both the forward and reverse immunology methods to further expand the available panel of therapeutic mHags for clinical application in routine therapies in the near future. Ultimate progress in mHag identification methods has been made by implementing the 1000 Genomes Project in existing genome-wide association analyses. Nonetheless, it will expectedly take several years before all patients with less common HLA types can be treated with mHag-directed therapies.
The first small clinical trials of patients treated with mHagspecific T-cell transfer have recently become available. These studies demonstrate the feasibility of inducing tumor-specific T-cell responses, even though clinical responses at this stage are generally short-lived and unpredictable. At this moment, clinical studies are also being performed to evaluate the feasibility, safety and efficacy of mHag-loaded DC vaccination. As it seems, both strategies hold great potential, but in the current stage require further optimization.
